Torrent Pharma

Torrent Pharma reported a 26% year-on-year increase in net profit to Rs 635 crore for the third quarter, driven by resilient domestic sales, improved operating leverage and disciplined cost management. The company’s earnings growth reflects strong traction in key therapeutic segments and stable demand across branded generics. Margin expansion and strategic portfolio optimization further supported profitability during the period. Analysts interpret the results as a sign of sustained execution strength amid global pricing pressures and regulatory complexities.

In one of India’s largest pharmaceutical mergers, Torrent Pharmaceuticals has agreed to acquire a controlling stake in JB Chemicals and Pharmaceuticals in a deal valued at Rs. 19,500 crore. The transaction, which includes promoter and employee stake purchases followed by a mandatory open offer, will propel Torrent to the position of India’s second most-valued pharmaceutical company.